Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (ACACIA-HCM)

Authors, Journal, Affiliations, Type, DOI

Overview

ACACIA-HCM is the first phase 3 randomized trial to meet its primary efficacy endpoints in symptomatic nonobstructive hypertrophic cardiomyopathy, a phenotype for which no pharmacotherapy had previously shown benefit. In 517 patients across 160 sites in 19 countries, aficamten titrated to a maximum tolerated dose of 20 mg improved the Kansas City Cardiomyopathy Questionnaire clinical summary score by 3.0 points and peak oxygen uptake by 0.67 ml/kg/min over placebo at 36 weeks, with a 57% reduction in NT-proBNP and a 14.1-percentage-point absolute increase in the proportion improving at least one NYHA class. The effect sizes are materially smaller than those aficamten achieves in obstructive disease, and reversible reduction of left ventricular ejection fraction below 50% occurred in 10.5% — threefold the rate in the obstructive trials. The result stands in direct contrast to ODYSSEY-HCM, in which mavacamten missed both co-primary endpoints in the same phenotype.

Keywords

Hypertrophic cardiomyopathy, nonobstructive HCM, aficamten, cardiac myosin inhibitor, peak oxygen uptake, cardiopulmonary exercise testing, KCCQ-CSS, NT-proBNP, left ventricular ejection fraction, LVOTO, exercise capacity, randomized controlled trial

Key Takeaways

Background and Rationale

Trial Design

Patients

Eligibility: age 18–85; nonobstructive HCM with maximum LV wall thickness ≥15 mm (≥13 mm with a known disease-causing variant or family history); resting LVOT gradient <30 mmHg and <50 mmHg with Valsalva; LVEF ≥60%.

Baseline Characteristics

Characteristic Aficamten (N=258) Placebo (N=259)
Age — years 55.7±16.2 54.5±16.0
Female sex — no. (%) 140 (54.3) 137 (52.9)
Pathogenic or likely pathogenic sarcomere variant — no./total (%) 124/197 (62.9) 107/193 (55.4)
Family history of HCM — no. (%) 105 (40.7) 106 (40.9)
Beta-blocker — no. (%) 203 (78.7) 197 (76.1)
Non-dihydropyridine calcium-channel blocker — no. (%) 31 (12.0) 39 (15.1)
Implantable cardioverter–defibrillator — no. (%) 107 (41.5) 105 (40.5)
Paroxysmal atrial fibrillation or flutter — no. (%) 78 (30.2) 68 (26.3)
Persistent or permanent atrial fibrillation — no. (%) 20 (7.8) 19 (7.3)
NYHA class II / III — no. (%) 171 (66.3) / 84 (32.6) 183 (70.7) / 74 (28.6)
KCCQ-CSS 66.3±16.2 65.0±15.4
Median NT-proBNP (IQR) — pg/ml 906 (508–1529) 893 (492–1609)
Median high-sensitivity troponin I (IQR) — ng/litre 30 (15–77) 28 (14–113)
Peak oxygen uptake — ml/kg/min 18.0±5.3 18.0±5.1
Percent of predicted peak oxygen uptake 55.3±13.1 54.9±12.7
Resting LVOT gradient — mmHg 9.1±6.1 8.2±4.6
LVOT gradient after Valsalva — mmHg 11.8±8.8 11.4±8.5
LV ejection fraction — % 67.9±4.0 68.4±3.4
Maximum LV wall thickness — mm 22.3±5.2 23.1±5.7
Left atrial volume index — ml/m² 36.8±10.9 37.5±11.9

Primary End Points

End point (change to week 36) Aficamten Placebo Difference (95% CI) P
KCCQ-CSS — points +11.4 (9.6–13.2) +8.4 (6.6–10.2) 3.0 (0.5–5.5) 0.02
Peak oxygen uptake — ml/kg/min +0.64 (0.32–0.95) −0.03 (−0.35 to 0.28) 0.67 (0.22–1.11) 0.003

Secondary End Points

End point Aficamten Placebo Effect (95% CI) P
≥1 NYHA class improvement — no. (%) 108 (41.9) 72 (27.8) common rate difference 14.1 pp (6.0–22.2) <0.001
Composite exercise z score +0.05 (−0.01 to 0.12) −0.09 (−0.14 to −0.05) 0.14 (0.07–0.22) <0.001
NT-proBNP proportional change — geometric LS mean 0.43 (0.39–0.46) 1.00 (0.93–1.08) ratio 0.43 (0.38–0.47) <0.001
Left atrial volume index — ml/m² −0.17 (−1.12 to 0.79) +1.13 (0.19–2.08) −1.30 (−2.64 to 0.04) 0.06
Time to first cardiovascular event — weeks (restricted mean) 68.2 (66.2–70.2) 68.8 (66.9–70.7) −0.6 (−3.3 to 2.2) —

Dose Escalation and Attained Doses

Safety

End point Aficamten (N=258) Placebo (N=258)
Any adverse event — no. (%) 207 (80.2) 217 (84.1)
Any serious adverse event — no. (%) 52 (20.2) 38 (14.7)
Leading to discontinuation of trial drug — no. (%) 18 (7.0) 5 (1.9)
Leading to interruption — no. (%) 19 (7.4) 9 (3.5)
LVEF <50% (reversible) — no. (%) 27 (10.5) 2 (0.8)
LVEF <50% with clinical heart failure — no. (%) 2 (0.8) 0
LVEF <40% — no. (%) 14 (5.4) 1 (0.4)

Interpretation

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated